Amantadine/Ribavirin

金刚烷胺/利巴韦林

Report date: 2022/12/07 17:52:23

Base Information

Drug NameAmantadine/Ribavirin

Drug Alias NameRibavirin/Amantadine利巴韦林+金刚烷胺金刚烷胺+利巴韦林Ribavirin+Amantadine利巴韦林/金刚烷胺 +[6]

ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues

Mechanisms of ActionInosine-5'-monophosphate dehydrogenase (IMPDH) inhibitorsmRNA guanylyltransferase inhibitorsGlutamate [NMDA] receptor antagonists +[4]

TargetsInosine-5'-monophosphate dehydrogenase (IMPDH)Glutamate [NMDA] receptorBacterial DNA-directed RNA polymerase +[4]

Therapy Area/IndicationsInfluenza, Human

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCanadaUnited StatesSingapore +[5]

CombinationsYes Amantadine Hydrochloride Ribavirin

Global Highest StatusPending (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesAdamas Pharmaceuticals Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesAdamas Pharmaceuticals Inc

Active IndicationsN/A

Inactive IndicationsInfluenza, Human

Other Information

ATC CodeN/A